HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
(Date:7/7/2015)... ... ... Law Group is pleased to announce the relocation of the firm's headquarters to 225 ... a state of the art building, located with easy access to New York City's ... "We are pleased to service our clients from such a premier location and we ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... SC&H Group, ... Service, which aims to give back to the community through company-wide volunteering efforts. , ... SC&H Group dedicate the day to assisting those in need throughout Baltimore and Washington ...
(Date:7/7/2015)... ... , ... At the end of June Pacific Prime Renewals team in Hong Kong announced ... by the Renewals Manager, Danielle Cotton, aims to not only reduce but eventually eliminate the ... explained, “We send anything between 300 and 600 pieces of paper per month. Not to ...
(Date:7/7/2015)... ... 07, 2015 , ... Summer is a great time to get outside and ... sharing some safety tips. , Jean Tapley, senior wellness coordinator at Amica, suggests the ... , Start slowly. Going from no activity to several hours of activity ...
(Date:7/7/2015)... ... ... Healthpointe is proud to announce the addition of Dr. Pedro S. Alupay to ... evaluating and treating patients with orthopedic complaints, such as lumbar back pain or cervical ... Biology from the University of the East, Manila, Dr. Alupay earned his Doctorate of ...
Breaking Medicine News(10 mins):Health News:SC&H Group Celebrates 9th Annual Day of Service 2Health News:Pacific Prime Hong Kong Renewals Team Starts Push to go Green 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 2Health News:Dr. Pedro S. Alupay, M.D., Now Providing Pain Management Services at Healthpointe in Irwindale 3
(Date:7/7/2015)... 30, 2015 Research ... of the "Deciphering Global Major Pharmaceutical Companies, ... their offering. It has been publicly ... involved in a series of challenges in the ... in significant overcapacities in small molecule product manufacturing; ...
(Date:7/7/2015)...   Decision Resources Group finds that ... management in the U.S. versus the EU5. In ... EU5 nephrologists from approximately 1,870 dialysis patient charts ... commonly used renal medications in dialysis patients; however, ... the two regions.      Other key findings ...
(Date:7/7/2015)... California and BANGALORE , ... , a global technology provider of innovative clinical trial ... Reports, (Industry Standard Research Reports) recent publication named " ... Provider Performance (2015) ". ISR Reports is one of ... pharmaceutical industry, and this report evaluated 22 EDC and ...
Breaking Medicine Technology:Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 2Deciphering Global Major Pharmaceutical Companies - New Outsourcing Demands and Strategies 3Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 2Similarities And Differences Exist When Comparing U.S. Versus EU5 Dialysis Patient Management 3Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 2Acceliant Ranked Highest in 'Overall Satisfaction' Amongst EDC Providers in ISR Reports' Recent Research 3
Cached News: